Myasthenia Gravis: FcRn Inhibitors and Complement-Directed Therapies
Sam Anderson
Pathophysiology-Based Treatment Selection
Myasthenia gravis treatment has been transformed by the arrival of complement inhibitors and FcRn antagonists — targeted therapies that address the underlying autoimmune pathophysiology rather than broadly suppressing the immune system. For the neurologist, neuromuscular specialist, or internist managing MG patients, understanding how to select among these newer agents and where they fit relative to established therapies (pyridostigmine, corticosteroids, conventional immunosuppressants) is essential for optimizing outcomes in a disease where treatment decisions are increasingly phenotype-driven.
Myasthenia gravis (MG) is driven by pathogenic autoantibodies at the neuromuscular junction. Anti-acetylcholine receptor (AChR) antibodies are present in 85% of generalized MG cases, while anti-muscle-specific kinase (MuSK) antibodies account for 5-8%[7]. The remaining seronegative cases may harbor low-affinity AChR antibodies detectable by cell-based assays. This antibody subtyping is critical for treatment selection: AChR-positive MG responds to complement inhibition (since AChR antibodies activate complement), while MuSK-MG (mediated by IgG4, which does not activate complement) responds to FcRn inhibitors and B-cell depletion but not complement-directed therapy. This parallels the antibody-subtype driven approach in immunotherapy oncology.
FcRn Inhibitors: Efgartigimod and Rozanolixizumab
Neonatal Fc receptor (FcRn) inhibitors accelerate IgG catabolism, reducing pathogenic antibody levels by 70-80% within 1-2 weeks[1]. Efgartigimod (Vyvgart) was FDA-approved in 2021 for generalized AChR-positive MG based on the ADAPT trial: 67.7% of treated patients achieved clinically meaningful improvement on the MG-ADL scale (4-point or more reduction) versus 29.7% for placebo (p<0.0001)[1]. The subcutaneous formulation with hyaluronidase (Vyvgart Hytrulo) was approved in 2023 for home administration. Rozanolixizumab received FDA approval in 2023 based on the MycarinG trial, showing MG-ADL improvement of -3.37 points versus -0.78 for placebo at day 43 (p<0.0001)[2]. Both agents produce cyclical IgG reduction, and optimal re-treatment timing is guided by clinical worsening.
Complement Inhibitors: Eculizumab and Ravulizumab
Terminal complement inhibition with the anti-C5 monoclonal antibody eculizumab (Soliris) was approved for refractory generalized AChR-positive MG based on the REGAIN trial, which showed a clinically meaningful MG-ADL response in 56% versus 31% for placebo[3]. Ravulizumab (Ultomiris), a long-acting anti-C5 antibody requiring infusion only every 8 weeks versus every 2 weeks for eculizumab, demonstrated noninferiority in the CHAMPION-MG trial with MG-ADL improvement of -3.1 points versus -1.4 for placebo (p<0.0001)[4]. Zilucoplan, a subcutaneous peptide C5 inhibitor, was approved in 2023 (RAISE trial: MG-ADL -4.39 versus -2.30 for placebo, p<0.0001)[5], offering the first self-injectable complement inhibitor.
Integrating Novel Therapies with Standard Treatment
Standard MG therapy begins with pyridostigmine for symptomatic relief (starting at 60 mg TID, titrated to 120 mg TID maximum). Immunosuppression with prednisone (0.5-1 mg/kg/day, tapered to the minimum effective dose) remains the most widely used disease-modifying therapy, often combined with steroid-sparing agents (azathioprine 2-3 mg/kg/day, mycophenolate 1-1.5 g BID, or rituximab 375 mg/m² for MuSK-MG). Novel targeted therapies (FcRn and complement inhibitors) are currently positioned for patients with refractory generalized disease or those requiring rapid treatment initiation. However, accumulating real-world data suggest earlier use may reduce cumulative steroid exposure and associated morbidity.
Thymectomy and Crisis Management
The MGTX trial definitively established the benefit of thymectomy in non-thymomatous AChR-positive generalized MG: at 5 years, thymectomy plus prednisone achieved greater improvement in QMG score (-19.2 versus -14.3, p=0.001)[6] with lower prednisone requirements (24 mg versus 48 mg alternate-day equivalent). Thymectomy is recommended for all patients with thymoma and for AChR-positive generalized MG patients aged 18-65. Myasthenic crisis (respiratory failure requiring intubation, distinct from pulmonary embolism) occurs in 15-20% of MG patients and is managed with IVIG (2 g/kg over 2-5 days) or plasma exchange (5 sessions over 10 days), with comparable efficacy (time to improvement 4-5 days). FcRn inhibitors are being studied as bridge therapy in crisis prevention.
Recognizing and Managing Myasthenic Crisis
Myasthenic crisis — respiratory failure from bulbar or diaphragmatic weakness requiring intubation — is the most dangerous acute complication and requires immediate intervention. Any patient with MG who reports worsening dysphagia, voice changes, or shortness of breath should be assessed urgently with bedside forced vital capacity (FVC) and negative inspiratory force (NIF). An FVC below 20 mL/kg or NIF weaker than -30 cmH2O should prompt ICU admission and consideration of intubation before respiratory arrest occurs. Crisis management includes IVIG or plasma exchange for rapid immunomodulation, identification and treatment of the precipitating factor (most commonly infection, medication changes, or surgical stress), and temporary hold of cholinesterase inhibitors if cholinergic excess is contributing to the clinical picture.
Limitations and the Evolving Treatment Landscape
The arrival of complement inhibitors and FcRn antagonists has transformed MG therapeutics, but these agents are expensive, require ongoing infusion or injection, and have limited long-term safety data beyond the registration trial periods. Whether they can replace chronic immunosuppression in a meaningful proportion of patients — rather than serving as add-on therapy — remains to be determined. The heterogeneity of MG (ocular versus generalized, AChR-positive versus MuSK-positive versus seronegative) means that treatment algorithms must be phenotype-specific, and the evidence base for each subgroup varies considerably. For the generalist managing a patient with MG, the most important principle is recognizing when to escalate and when to involve neuromuscular subspecialty expertise — particularly for refractory disease and crisis prevention.
References
- Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial PubMed 34644473
- Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study PubMed 37059072
- Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study PubMed 28605400
- Ravulizumab in Myasthenia Gravis: A Phase 3 Trial PubMed 37164098
- Zilucoplan in patients with moderate-to-severe generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study PubMed 37164097
- Randomized Trial of Thymectomy in Myasthenia Gravis PubMed 27509100
- Myasthenia gravis PubMed 26515624
Frequently Asked Questions
What is the response rate for efgartigimod in generalized myasthenia gravis?
Do complement inhibitors work in MuSK-positive myasthenia gravis?
How does ravulizumab compare to eculizumab for myasthenia gravis?
What is the role of thymectomy in myasthenia gravis?
How is myasthenic crisis managed?
What is zilucoplan for myasthenia gravis?
Explore This Topic in Ailva
Ailva is a free clinical intelligence platform for NPI-verified US physicians. Get evidence-based answers with verified citations from 16M+ indexed papers — plus free CME credits.
Founder of Ailva.ai | Former Director of Research and Author of 200+ Medically Reviewed Articles | Editor-in-Chief of EudaLife Magazine